EUCTR2009-015162-57-IT进行中（未招募）不适用
A Phase 3, 40-week. Active-controlled, Double-blind, Double-Dummy Extension Study of Preladenant in Subjects with moderate to severe Parkinson`s Disease. - ND
Schering-Plough Research Institute, division of Schering Corporation0 个研究点目标入组 750 人开始时间: 2011年4月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must have completed P04938 or P07037. • Each subject (or subject’s legal representative) must be willing and able to provide written informed consent for the P06153. For a subject who is unable to provide independent consent, a legal representative may provide written informed consent. • Subjects must be able to adhere to dose and visit schedules. • Subjects must be taking levodopa (L-dopa). • Subjects may be taking any of the additional adjunct PD medications shown in the table below. Note: Subjects taking only L-dopa are permitted to enroll in this trial. Amantadine Anticholinergics Dopa decarboxylase inhibitors Dopamine agonists Entacapone L-dopa • Each subject must have results of clinical laboratory tests (hematology, blood chemistries, and urinalysis) within normal limits or clinically acceptable to the investigator as evidenced by the last available test results from the parent study (P04938 or P07037), and no results fall within the parameters for exclusion described below in the exclusion criterion for liver-related findings. • There has been no change in, or there has been no finding to warrant checking, serology status (for cytomegalovirus [CMV], Epstein-Barr virus [EBV], and Hepatitis B, C, and E). Each subject must have results of a physical examination within normal limits, including blood pressure, within normal limits or clinically acceptable limits to the investigator, and not within the parameters for exclusion described below in the exclusion criterion for blood pressure. • All subjects that are sexually active or plan to be sexually active agree to use a highly effective method of birth control while the subject is in the study and for 2 weeks after the last dose of study drug. A male subject must not donate sperm within 2 weeks after the last dose of study drug. Complete details regarding contraceptive requirements are specified in protocol Section 7.7.1.7.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject must not have discontinued from P04938 or P07037 for any reason. • A subject must not have a severe or ongoing unstable medical condition (eg, any form of clinically significant cardiac disease, symptomatic orthostatic hypotension, seizures, or alcohol/drug dependence). • A subject must not have poorly controlled diabetes ( eg, HbA1c ?8.5) or significantly abnormal renal function (eg, creatinine ?2.0 mg/dL) in the opinion of the investigator. • As a continuation of the liver-related withdrawal criteria from the parent studies (P04938 and P07037), any subject with elevated values for alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin (T-BIL), as evidenced by the most recent chemistry panel results in the parent study, meeting any one of the following criteria: • ALT or AST ?8 x ULN. • ALT or AST ?5 x ULN for more than 2 weeks. • ALT or AST ?3 x ULN and (T-BIL ?2 x ULN or international normalized ratio [INR] ?1.5 that is not due to anti-coagulation) at the same visit. • ALT or AST ?3 x ULN with the appearance of worsening fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (?5%). • As a continuation of the blood pressure (BP) withdrawal criteria from the parent studies (P04938 and P07037), any subject meeting the following criteria for the second of two consecutive visits separated by 7 days (ie, the subject met one of the BP criteria once already, 7 days before the P06153 Screening visit): • Systolic BP ?180 mm Hg or diastolic BP ?105 mm Hg, or • An elevation from Baseline BP in the parent study (P04938 or P07037) of systolic BP ?40 mm Hg or diastolic BP ?20 mm Hg. • A subject must not have a history within the past 5 years of a primary or recurrent malignant disease with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with a normal prostate-specific antigen (PSA) post resection. • A subject must not have an average daily consumption of more than three 4-ounce glasses (180 mL) of wine or the equivalent. • Prohibited Concomitant Medications: A subject should not take or start taking any treatment listed in the table below. A subject must not have received any treatment listed in the table below more recently than the indicated period before Day 1 of P06153. Note: Warnings and Contraindications detailed in the Prescribing Information for the allowed medications (shown in the inclusion criteria) must be followed.A subject must not have allergy/sensitivity to the investigational products or their excipients. • A female subject must not be breast-feeding or considering breast-feeding. • A female subject must not be pregnant or intending to become pregnant. • A subject must not have any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the trial evaluations or optimal participation in the trial.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644